Immuneering will discuss updated survival and safety data for pancreatic cancer treatment in a conference call on September 29, 2025.
Quiver AI Summary
Immuneering Corporation announced a conference call and live webcast scheduled for September 29, 2025, to discuss updated overall survival and safety data from a study on pancreatic cancer patients treated with their drug, atebimetinib, combined with mGnP. The data, which shows promising results from a trial with 34 patients and a median follow-up of nine months, was initially revealed in a press release on September 24 and will be presented at the PanCAN Scientific Summit 2025. CEO Ben Zeskind emphasized the company's commitment to transparency and community engagement regarding these findings. Interested individuals can access the conference via a provided webcast link or by phone. Immuneering specializes in developing innovative cancer treatments, particularly their lead candidate atebimetinib, aimed at improving outcomes for patients with MAPK pathway-driven tumors.
Potential Positives
- Immuneering Corporation will present updated overall survival and safety data for atebimetinib at the PanCAN Scientific Summit, highlighting their commitment to transparency and engagement with the scientific community.
- The conference call allows investors and interested parties to engage directly with the company and gain insights into promising results from a clinical trial involving pancreatic cancer patients.
- Atebimetinib is positioned as an innovative treatment in the oncology space, aiming to improve durability and tolerability for patients with MAPK pathway-driven tumors, potentially expanding treatment options for a challenging disease.
Potential Negatives
- The press release suggests that data is still in early stages (only 9 months median follow-up), which may raise concerns about the reliability and long-term efficacy of the treatment being discussed.
- The company is still classified as a clinical-stage oncology company, indicating that it has not yet brought a product to market, which can create uncertainty for investors regarding future revenue and viability.
FAQ
What is the purpose of the Immuneering conference call on September 29, 2025?
The conference call will discuss updated survival and safety data in pancreatic cancer patients treated with atebimetinib.
How can I join the Immuneering conference call?
You can join the call via the webcast link or by dialing (800) 715-9871, referencing conference ID 9502940.
What were the results mentioned in the press release on September 24, 2025?
The press release highlighted updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib.
Where can I find the webcast replay of the conference call?
A webcast replay will be available in the “Investors” section of Immuneering’s website.
What is atebimetinib and its significance in cancer treatment?
Atebimetinib is an oral Deep Cyclic Inhibitor designed to improve treatment durability and tolerability for MAPK pathway-driven tumors, including pancreatic cancers.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMRX Insider Trading Activity
$IMRX insiders have traded $IMRX stock on the open market 12 times in the past 6 months. Of those trades, 12 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IMRX stock by insiders over the last 6 months:
- THOMAS J. SCHALL has made 2 purchases buying 49,985 shares for an estimated $124,065 and 0 sales.
- BENJAMIN J. ZESKIND (PRESIDENT AND CEO) has made 3 purchases buying 31,000 shares for an estimated $85,023 and 0 sales.
- PETER FEINBERG purchased 25,000 shares for an estimated $63,187
- BRETT MATTHEW HALL (CHIEF SCIENTIFIC OFFICER) has made 2 purchases buying 13,422 shares for an estimated $34,616 and 0 sales.
- DIANA HAUSMAN has made 2 purchases buying 5,500 shares for an estimated $19,862 and 0 sales.
- HAROLD EUGENE BRAKEWOOD (Chief Business Officer) purchased 1,900 shares for an estimated $4,804
- LEAH R NEUFELD (CHIEF PEOPLE OFFICER) purchased 700 shares for an estimated $2,498
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IMRX Hedge Fund Activity
We have seen 19 institutional investors add shares of $IMRX stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 659,009 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,220,860
- MORGAN STANLEY removed 266,132 shares (-57.0%) from their portfolio in Q2 2025, for an estimated $896,864
- MARSHALL WACE, LLP removed 234,105 shares (-29.0%) from their portfolio in Q2 2025, for an estimated $788,933
- FMR LLC added 221,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $744,770
- ROCKEFELLER CAPITAL MANAGEMENT L.P. removed 177,377 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $269,613
- BLACKROCK, INC. added 106,228 shares (+33.6%) to their portfolio in Q2 2025, for an estimated $357,988
- MANUFACTURERS LIFE INSURANCE COMPANY, THE removed 82,667 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $278,587
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IMRX Analyst Ratings
Wall Street analysts have issued reports on $IMRX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 09/26/2025
- Oppenheimer issued a "Outperform" rating on 09/25/2025
- Needham issued a "Buy" rating on 09/15/2025
- Mizuho issued a "Outperform" rating on 06/18/2025
To track analyst ratings and price targets for $IMRX, check out Quiver Quantitative's $IMRX forecast page.
$IMRX Price Targets
Multiple analysts have issued price targets for $IMRX recently. We have seen 4 analysts offer price targets for $IMRX in the last 6 months, with a median target of $15.5.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $20.0 on 09/26/2025
- Jay Olson from Oppenheimer set a target price of $30.0 on 09/25/2025
- Ami Fadia from Needham set a target price of $11.0 on 09/15/2025
- Graig Suvannavejh from Mizuho set a target price of $10.0 on 06/18/2025
Full Release
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up.
“These exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed during our conference call on Monday. We are committed to ensuring the community has multiple opportunities to engage with and understand these important results,” said Ben Zeskind, Ph.D., CEO of Immuneering.
Individuals interested in listening to the live conference call may do so through this webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations and reference conference ID 9502940. A webcast replay will be available from the “Investors” section of the Company’s website here . The Immuneering September 2025 corporate presentation can be found here and the September 24, 2025 press release announcing updated overall survival and safety data in first-line pancreatic cancer patients can be found here .
About Immuneering
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit
www.immuneering.com
.
Media Contact:
Carson Creehan
817-412-1096
[email protected]
Investor Contact:
Laurence Watts
619-916-7620
[email protected]
